Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 8/20 | 0.44 |
| ▸ | PTGES | O14684 | 2/20 | 0.38 |
| ▸ | CNR2 | P34972 | 2/20 | 0.37 |
| ▸ | FPR2 | P25090 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | TYK2 | P29597 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | CASR | P41180 | 1/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2488940 | 0.91 | SCN9A (0.40) | SCN9AFPR2ALDH1A1POLB | |
| SCHEMBL12210846 | 0.91 | SCN9A (0.39) | SCN9APTGESCNR2FPR2ALDH1A1 | |
| SCHEMBL15060821 | 0.90 | SMN1; SMN2 (0.38) | SCN9AALDH1A1JAK2JAK1TYK2 | |
| SCHEMBL12210914 | 0.89 | ALDH1A1 (0.43) | ALDH1A1POLB | |
| SCHEMBL2492918 | 0.88 | ALDH1A1 (0.35) | SCN9APTGESFPR2ALDH1A1F2 | |
| SCHEMBL12210812 | 0.88 | SCN9A (0.47) | SCN9AFPR2ALDH1A1JAK2JAK1 | |
| SCHEMBL2489326 | 0.85 | SCN9A (0.39) | SCN9APTGESFPR2ALDH1A1 | |
| SCHEMBL13273948 | 0.85 | ALDH1A1 (0.38) | SCN9AFPR2ALDH1A1F2TRPV3 | |
| SCHEMBL12210837 | 0.83 | MAOB (0.35) | SCN9APTGESALDH1A1F2 | |
| SCHEMBL13274163 | 0.83 | SCN9A (0.51) | SCN9AFPR2ALDH1A1ALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2380881-B1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | SUMITOMO DAINIPPON PHARMA CO LTD (JP) | 2017-01-25 | — | — | EP | disclosed |
| US-20130303535-A1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | Sumitomo Pharma Co., Ltd. (JP) | 2013-11-14 | — | — | US | disclosed |
| US-8471038-B2 | Bicyclic heterocyclic compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-06-25 | — | — | US | disclosed |
| US-20110294804-A1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-12-01 | — | — | US | disclosed |
| EP-2380881-A1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2011-10-26 | — | — | EP | disclosed |
| WO-2010074193-A1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | 大日本住友製薬株式会社 (JP) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294804-A1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | OPRL1, SCN1B, OPRD1 | SCN9A 24/4885PTGES 2980/4885CNR2 11/4885 |
| US-20130303535-A1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | OPRL1, SCN1B, OPRD1 | SCN9A 24/4885PTGES 2980/4885CNR2 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.